P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE

• D. Belada,
• S. Leppä,
• B. E. Wahlin,
• M. Nijland,
• J. H. Christensen,
• S. de Vos,
• H. Holte,
• K. M. Linton,
• A. Abbas,
• L. Wang,
• M. Dinh,
• B. Elliott,
• L. Falchi

Affiliations

D. Belada

1 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czechia

S. Leppä

2 Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland

B. E. Wahlin

3 Karolinska Institutet, Stockholm, Sweden

M. Nijland

4 University Medical Center Groningen and University of Groningen, Groningen, Netherlands

J. H. Christensen

5 Odense University Hospital, Odense, Denmark

S. de Vos

6 Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, United States of America

H. Holte

7 Oslo University Hospital and KG Jebsen Center for B-cell Malignancies, Oslo, Norway

K. M. Linton

8 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom

A. Abbas

9 Genmab, Princeton

L. Wang

9 Genmab, Princeton

M. Dinh

10 AbbVie, North Chicago

B. Elliott

9 Genmab, Princeton

L. Falchi

11 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, United States of America